10X Genomics, Inc.

10X Genomics, Inc. has seen a notable rise in its stock price, achieving an 11.72% increase on June 15, 2026. The company has outperformed the S&P 500 over the past month and year, with strong operating cash flow and a low debt-equity ratio, indicating a solid financial position.

10X Genomics, Inc. saw a significant stock decline today, contrasting with the broader market's performance. Despite this, the company has achieved a remarkable annual return and consistent positive results over the past five quarters. High institutional ownership reflects strong investor confidence, though concerns about stock volatility persist.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. With a market capitalization of USD 2,132 million, the company operates in a competitive biotechnology sector, showcasing its potential despite being loss-making and not offering dividends.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year with a 33.41% gain. The company, with a market capitalization of USD 2,132 million, showcases a unique financial structure and continues to evolve within the competitive biotechnology sector.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. The company has seen a notable performance rise over the past year, with a market capitalization of USD 2,132 million. Despite ongoing losses, it continues to focus on growth and innovation in biotechnology.

10X Genomics, Inc. has experienced notable stock performance, with significant gains over various time frames, including a 215.91% increase over the past year. The company has reported strong financial results, including a record operating cash flow and a low debt-equity ratio, indicating a solid financial position.

10X Genomics, Inc. has achieved a new 52-week high, reflecting strong performance over the past year. The company, with a market capitalization of USD 2,132 million, is positioned in the small-cap sector. Despite losses, it maintains a notable price-to-book ratio and a unique financial structure.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. The company, with a market capitalization of USD 2,132 million, has seen a 17.58% performance rise over the past year, despite being loss-making and not offering dividends.

10X Genomics, Inc. has recently revised its evaluation amid current market dynamics. The stock is priced at $25.24, reflecting a notable annual performance with a 214.32% return. Technical indicators present a mixed outlook, while the company has shown significant volatility over the past year.

10X Genomics, Inc. has achieved a new 52-week high, reflecting a notable performance with a 14.29% gain over the past year. Despite this progress, the company remains unprofitable, with a negative return on equity and no dividends offered, highlighting ongoing financial challenges.

10X Genomics, Inc. has recently undergone an evaluation revision amid current market dynamics. The company’s stock is priced at $23.00, reflecting a notable annual performance with a 165.28% return. Technical indicators present a mixed outlook, highlighting the company's volatility and the need for continued performance monitoring.

10X Genomics, Inc. has shown strong market performance, with notable gains over the past month and year, significantly outperforming the S&P 500. The company boasts solid financial metrics, including a robust operating cash flow and a high level of institutional holdings, reflecting investor confidence.

10X Genomics, Inc. has achieved a new 52-week high of USD 23.60, significantly up from its low of USD 6.94. Despite a modest one-year performance of 3.79%, the company maintains a market capitalization of USD 2,132 million, reflecting its position in the competitive biotechnology sector.

10X Genomics, Inc. has seen a significant rise in its stock performance, reaching an intraday high. Over the past year, it has outperformed the S&P 500, despite recent short-term declines. The company enjoys strong institutional ownership and has achieved its highest operating cash flow, though it faces challenges with negative return on equity.

10X Genomics, Inc. faced a notable decline in its stock price, reaching an intraday low amid a challenging trading session. Despite a significant drop over the past week, the company has strong institutional support and a market capitalization of USD 2,412 million, with no dividend currently offered.

10X Genomics, Inc. has faced a significant stock decline today, reaching an intraday low. Despite recent challenges, the company has shown mixed performance metrics, with a notable annual return and strong institutional ownership. However, long-term performance over three and five years remains concerning.

10X Genomics, Inc. has recently experienced a stock price decline, reflecting its complex market dynamics. While the company has outperformed the S&P 500 over the past year, it has faced significant challenges in longer-term performance. Technical indicators present mixed signals, indicating varying market sentiments.

10X Genomics, Inc. has shown notable market activity, gaining 12.56% today and reaching an intraday high of USD 22.17. The company has achieved a 15.32% increase over the past week and an impressive 89.96% return over the last year, significantly outperforming the S&P 500.

10X Genomics, Inc. has recently revised its evaluation amid notable stock price fluctuations, currently at $22.13. The company has achieved a nearly 90% return over the past year, significantly outperforming the S&P 500. Technical indicators show mixed performance, with some bullish trends and neutral momentum signals.